drugset / Trial / NCT01995838

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia

NCT01995838

Phase 2 Completed 291 enrolled Eisai Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, parallel-group, Bayesian adaptive, dose response study in subjects with chronic insomnia. Subjects will be randomized to 1 of 6 doses of E2006 (1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg) or placebo.

Timeline

Start
2013-11-13
Primary completion
2014-04-29
Completion
2014-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Lemborexant Small molecule 1 mg Oral
Subject Lemborexant Small molecule 2.5 mg Oral
Subject Lemborexant Small molecule 5 mg Oral
Subject Lemborexant Small molecule 10 mg Oral
Subject Lemborexant Small molecule 15 mg Oral
Subject Lemborexant Small molecule 25 mg Oral

Indications